Diagnostics Archives

News and Trends 18 Feb 2020

OncoDNA Secures €19M to Progress Precision Cancer Treatment Technology

Belgian biotech OncoDNA has raised €19M in Series B funding to further develop its cancer diagnostic and therapeutic decision-making software. The funding was led by Vesalius Biocapital, a Luxembourg-based VC investor, Swiss VC firm Swisscanto Invest by Zürcher Kantonalbank, and Belgian VC company SFPI-FPIM. Early investors in the company such as CPH Bank also contributed […]

February 18, 2020 - 2 minutesmins - By Helen Albert

stilla technologies pcr molecular diagnostics

News and Trends 11 Feb 2020

French Biotech Raises €20M to Make Precision Molecular Diagnostics

Stilla Technologies has raised a €20M Series C round to fund its mission to produce next-generation microchips that make molecular diagnostics more precise and user-friendly than currently available lab technology. Contributors to the round included Stilla’s existing investors, such as Illumina Ventures, Kurma Partners and Idinvest Partners. Stilla also added the Chinese company TUS-Holdings to […]

February 11, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 30 Jan 2020

Austrian Genomics Company Joins Fight Against Coronavirus

Ares Genetics will use next-generation sequencing technology from the Chinese genomics company BGI Group to track and control the spread of a new coronavirus originating in China. A new strain of coronavirus, dubbed 2019-nCoV and originating in the Chinese city of Wuhan, has caused widespread concern in recent weeks. While only 20% of people with […]

January 30, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 24 Jan 2020

€6M Seed Round to Develop First Urine Test for Kidney Cancer

The Swedish biotech Elypta has raised a seed round worth €6.1M to fund a clinical trial of a urine test for signs of recurrent kidney cancer, which could improve patient follow-up after surgery. The seed round was led by the Swedish VC firm Industrifonden. Other investors in the round included the VC impact fund of […]

January 24, 2020 - 3 minutesmins - By Jonathan Smith

centogene rare diseases diagnostic ipo nasdaq

News and Trends 7 Nov 2019

€51M Nasdaq IPO Will Fund Centogene’s Rare Disease Diagnostics

The German company Centogene has raised €50.6M ($56M) in an IPO on the Nasdaq Stock Exchange to fund the development of diagnostics technology that could improve the treatment of rare diseases. The fundraise fell under Centogene’s target value of €54M ($60M). A part of the proceeds will fuel the development of biomarkers that Centogene will […]

November 7, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 31 Oct 2019

European Project Launches to Tailor Autoimmune Disease Treatments

Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […]

October 31, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 28 Oct 2019

AI-Driven Antibiotic Susceptibility Test Launched in Austria

Ares Genetics, an Austrian subsidiary of the German Curetis Group, has launched an early access program for its AI-driven antibiotic susceptibility test. The company, which focuses on molecular diagnostics, has a large, regularly updated database of genetic information on disease-causing microbes including strains showing antimicrobial resistance. The new test uses high-resolution sequencing to gain genetic […]

October 28, 2019 - 2 minutesmins - By Helen Albert

breathomix breath diagnostics lung cancer

News and Trends 19 Sep 2019

Dutch ‘Electronic Nose’ Predicts Cancer Immunotherapy Success

A diagnostic device measuring chemicals in the breath, developed by the Dutch company Breathomix, was able to identify lung cancer patients that wouldn’t respond to cancer immunotherapy with unprecedented accuracy. Researchers at the University of Amsterdam tested the device on 143 lung cancer patients, who were going to receive immunotherapy in the form of the […]

September 19, 2019 - 2 minutesmins - By Jonathan Smith

sepsis diagnosis abionic blood infection

News and Trends 16 Sep 2019

Sepsis Diagnosed in 5 Minutes Instead of 24 Hours with Swiss Biotech’s Test

A test for sepsis developed by the Swiss diagnostics company Abionic was able to predict within just five minutes which intensive care patients are likely to develop sepsis in a clinical study. In the pivotal study, Abionic trialed the blood test in 300 intensive care patients with a high risk of sepsis. Abionic found that […]

September 16, 2019 - 3 minutesmins - By Jonathan Smith

oncimmune liquid biopsy lung cancer test

News and Trends 10 Sep 2019

Blood Test Increases Early Lung Cancer Diagnosis in UK Trial

A blood test for anti-cancer antibodies, developed by the UK diagnostics company Oncimmune, detected more early cases of lung cancer than standard clinical monitoring procedures in a trial with more than 12,000 patients. Oncimmune’s trial recruited 12,209 patients with a high risk of developing lung cancer through smoking and family history, and monitored them for […]

September 10, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Jul 2019

European Biotech: The Insider View

How has CRISPR changed drug development? How do you negotiate a good partnership? What are some of the hard decisions to make in founding a biotech? These are some of the questions that industry experts answered at Labiotech’s first Insider Day. Held exclusively for members, Labiotech’s first Insider Day aimed to explore the different aspects […]

July 7, 2019 - 10 minutesmins - By Jonathan Smith

In Depth 4 Jun 2019

Ultra-Fast Diagnostics Could Transform Sexual Health

Each day more than one million people around the world acquire sexually transmitted infections, with a profound impact on sexual and reproductive health across the globe. Biotechs across Europe are developing rapid diagnostics for some of the most common STIs. It’s difficult to comprehend the sheer scale of the number of people affected by sexually […]

June 4, 2019 - 7 minutesmins - By David Cox

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us